Amphastar Pharmaceuticals (AMPH) Revenue & Revenue Breakdown
Amphastar Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$593.24M
Latest Revenue (Q)
$182.39M
Main Segment (Y)
Active Pharmaceutical Ingredient Segment
Main Geography (Y)
U
Amphastar Pharmaceuticals Revenue by Period
Amphastar Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $593.24M | 18.89% |
| 2022-12-31 | $498.99M | 13.98% |
| 2021-12-31 | $437.77M | 25.13% |
| 2020-12-31 | $349.85M | 8.53% |
| 2019-12-31 | $322.36M | 9.40% |
| 2018-12-31 | $294.67M | 22.69% |
| 2017-12-31 | $240.18M | -5.87% |
| 2016-12-31 | $255.16M | 1.45% |
| 2015-12-31 | $251.52M | 19.51% |
| 2014-12-31 | $210.46M | -8.37% |
| 2013-12-31 | $229.68M | 12.41% |
| 2012-12-31 | $204.32M | 72.63% |
| 2011-12-31 | $118.36M | - |
Amphastar Pharmaceuticals generated $593.24M in revenue during NA 2023, up 18.89% compared to the previous quarter, and up 201.33% compared to the same period a year ago.
Amphastar Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $182.39M | 6.14% |
| 2024-03-31 | $171.84M | -3.52% |
| 2023-12-31 | $178.10M | -1.36% |
| 2023-09-30 | $180.56M | 23.91% |
| 2023-06-30 | $145.71M | 4.06% |
| 2023-03-31 | $140.02M | 3.70% |
| 2022-12-31 | $135.02M | 12.40% |
| 2022-09-30 | $120.13M | -2.70% |
| 2022-06-30 | $123.47M | 2.57% |
| 2022-03-31 | $120.37M | -0.43% |
| 2021-12-31 | $120.89M | 7.74% |
| 2021-09-30 | $112.20M | 10.36% |
| 2021-06-30 | $101.66M | -1.32% |
| 2021-03-31 | $103.02M | 7.40% |
| 2020-12-31 | $95.92M | 14.97% |
| 2020-09-30 | $83.43M | -2.77% |
| 2020-06-30 | $85.81M | 1.32% |
| 2020-03-31 | $84.69M | 1.57% |
| 2019-12-31 | $83.38M | 4.05% |
| 2019-09-30 | $80.14M | 1.38% |
| 2019-06-30 | $79.05M | -0.93% |
| 2019-03-31 | $79.79M | -11.04% |
| 2018-12-31 | $89.69M | 18.73% |
| 2018-09-30 | $75.54M | 6.34% |
| 2018-06-30 | $71.04M | 21.66% |
| 2018-03-31 | $58.39M | -3.33% |
| 2017-12-31 | $60.40M | 4.29% |
| 2017-09-30 | $57.92M | -11.15% |
| 2017-06-30 | $65.19M | 15.03% |
| 2017-03-31 | $56.67M | -10.82% |
| 2016-12-31 | $63.54M | -1.06% |
| 2016-09-30 | $64.22M | -5.60% |
| 2016-06-30 | $68.03M | 14.60% |
| 2016-03-31 | $59.37M | -22.81% |
| 2015-12-31 | $76.91M | 20.42% |
| 2015-09-30 | $63.87M | 18.60% |
| 2015-06-30 | $53.85M | -5.33% |
| 2015-03-31 | $56.89M | 1.81% |
| 2014-12-31 | $55.88M | -6.42% |
| 2014-09-30 | $59.71M | 21.85% |
| 2014-06-30 | $49.00M | 6.83% |
| 2014-03-31 | $45.87M | -16.41% |
| 2013-12-31 | $54.88M | -7.49% |
| 2013-09-30 | $59.32M | -5.13% |
| 2013-06-30 | $62.52M | 18.05% |
| 2013-03-31 | $52.96M | - |
Amphastar Pharmaceuticals generated $182.39M in revenue during Q2 2024, up 6.14% compared to the previous quarter, and up 130.26% compared to the same period a year ago.
Amphastar Pharmaceuticals Revenue Breakdown
Amphastar Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Active Pharmaceutical Ingredient Segment | $18.48M | $20.36M | $23.61M |
Amphastar Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 20: Active Pharmaceutical Ingredient Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active Pharmaceutical Ingredient Segment | $6.94M | $5.14M | $8.12M | $2.10M | $4.87M | $3.39M | $5.39M | $4.41M | $5.31M | $5.25M | $3.78M | $7.80M | $5.28M | - |
| Finished Pharmaceutical Products Segment | - | - | - | - | - | - | - | - | - | - | $82.93M | - | - | - |
Amphastar Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Active Pharmaceutical Ingredient Segment (100.00%).
Amphastar Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| U | $333.09M | $304.90M | $279.12M |
| Active Pharmaceutical Ingredient Segment | $18.48M | - | - |
| C | $3.16M | $1.48M | - |
Amphastar Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 20: U (93.90%), Active Pharmaceutical Ingredient Segment (5.21%), and C (0.89%).
Quarterly Revenue by Country
| Country | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active Pharmaceutical Ingredient Segment | $6.94M | - | - | - | - | - | - | - | - | - | - | - | - |
| U | $95.19M | $99.17M | $90.72M | $79.41M | $81.90M | $81.06M | $77.59M | $76.07M | $74.78M | $76.46M | $72.48M | $68.56M | $53.10M |
| C | $1.13M | $1.12M | $679.00K | $1.96M | $295.00K | $228.00K | $438.00K | $59.00K | $984.00K | - | - | - | - |
Amphastar Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 21: U (92.19%), Active Pharmaceutical Ingredient Segment (6.72%), and C (1.09%).
Amphastar Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| EVO | Evotec SE | $781.43M | $208.73M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| SUPN | Supernus Pharmaceuticals | $607.52M | $168.32M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| EOLS | Evolus | $199.72M | $66.22M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
AMPH Revenue FAQ
What is Amphastar Pharmaceuticals’s yearly revenue?
Amphastar Pharmaceuticals's yearly revenue for 2023 was $593.24M, representing an increase of 18.89% compared to 2022. The company's yearly revenue for 2022 was $498.99M, representing an increase of 13.98% compared to 2021. AMPH's yearly revenue for 2021 was $437.77M, representing an increase of 25.13% compared to 2020.
What is Amphastar Pharmaceuticals’s quarterly revenue?
Amphastar Pharmaceuticals's quarterly revenue for Q2 2024 was $182.39M, a 6.14% increase from the previous quarter (Q1 2024), and a 25.17% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $171.84M, a -3.52% decrease from the previous quarter (Q4 2023), and a 22.72% increase year-over-year (Q1 2023). AMPH's quarterly revenue for Q4 2023 was $178.1M, a -1.36% decrease from the previous quarter (Q3 2023), and a 31.91% increase year-over-year (Q4 2022).
What is Amphastar Pharmaceuticals’s revenue growth rate?
Amphastar Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 35.51%, and for the last 5 years (2019-2023) was 84.03%.
What are Amphastar Pharmaceuticals’s revenue streams?
Amphastar Pharmaceuticals's revenue streams in c 20 are Active Pharmaceutical Ingredient Segment
What is Amphastar Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of Amphastar Pharmaceuticals was Active Pharmaceutical Ingredient Segment. This segment made a revenue of $18.48M, representing 100.00% of the company's total revenue.